News for Immunomedics, Inc. - Google Finance

IMMUNOMEDICS, INC. : IMMUNOMEDICS TO PRESENT AT WELLS FARGO ...

Fri, 14 Jun 2013 12:51:24 GMT

IMMUNOMEDICS, INC. : IMMUNOMEDICS TO PRESENT AT WELLS FARGO ...
4-traders (press release) - Jun 14, 2013

Morris Plains, NJ, June 14, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibodybased products for the targeted treatment of cancer, autoimmune and other serious ...

IMMUNOMEDICS, INC. : IMMUNOMEDICS DEVELOPS NOVEL DUAL SYSTEM ...

Mon, 10 Jun 2013 15:22:15 GMT

IMMUNOMEDICS, INC. : IMMUNOMEDICS DEVELOPS NOVEL DUAL SYSTEM ...
4-traders (press release) - Jun 10, 2013

Vancouver, BC, June 10, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody- based products for the targeted treatment of cancer, autoimmune and other serious ...

Immunomedics Develops Novel Dual System for Tumor Detection and Imaging - NASDAQ

IMMUNOMEDICS, INC. : COMBINATION OF 90Y-EPRATUZUMAB AND ...

Tue, 11 Jun 2013 13:40:50 GMT

IMMUNOMEDICS, INC. : COMBINATION OF 90Y-EPRATUZUMAB AND ...
4-traders (press release) - Jun 11, 2013

COMBINATION OF 90Y-EPRATUZUMAB AND VELTUZUMAB IS ACTIVE IN NON-HODGKIN LYMPHOMA -- Results on Potential New Treatment Regimen Presented at SNMMI 2013 Annual Meeting -- Vancouver, BC, June 11, 2013 --- Immunomedics, Inc.

IMMUNOMEDICS, INC. : IMMUNOMEDICS PRESENTS CLINICAL PROGRESS ...

Thu, 30 May 2013 13:52:23 GMT

IMMUNOMEDICS, INC. : IMMUNOMEDICS PRESENTS CLINICAL PROGRESS ...
4-traders (press release) - May 30, 2013

Morris Plains, NJ, May 30, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody- based products for the targeted treatment of cancer, autoimmune and other serious ...

IMMUNOMEDICS, INC. : 90Y-EPRATUZUMAB STUDY SHOWS IMPROVEMENT ...

Mon, 10 Jun 2013 21:01:09 GMT

IMMUNOMEDICS, INC. : 90Y-EPRATUZUMAB STUDY SHOWS IMPROVEMENT ...
4-traders (press release) - Jun 10, 2013

90Y-EPRATUZUMAB STUDY SHOWS IMPROVEMENT OF THERAPY RESULTS FOLLOWING R-CHOP Vancouver, BC, June 10, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of ...

Big Winners: Clearwire Corporation (NASDAQ:CLWR), Immunomedics, Inc ...

Fri, 31 May 2013 12:48:12 GMT

Big Winners: Clearwire Corporation (NASDAQ:CLWR), Immunomedics, Inc ...
Openglobe - May 31, 2013

Clearwire Corporation (NASDAQ:CLWR) shares jumped 29.31% to $4.50. The company on May 30 acknowledged that DISH Network Corporation (NASDAQ: DISH) (“DISH”) has commenced an unsolicited cash tender offer to acquire all outstanding common ...

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) and Immunomedics Inc ...

Fri, 31 May 2013 12:24:22 GMT

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) and Immunomedics Inc ...
SBWire (press release) - May 31, 2013

Immunomedics Inc. (NASDAQ:IMMU) a biopharmaceutical company that engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the ...

Now Available: Immunomedics, Inc. - Product Pipeline Review - 2013

Wed, 29 May 2013 01:39:44 GMT

Now Available: Immunomedics, Inc. - Product Pipeline Review - 2013
ClickPress (press release) - May 29, 2013

[ClickPress, Mon May 27 2013] Global Market Direct's pharmaceuticals report, "Immunomedics, Inc. - Product Pipeline Review - 2013" provides data on the Immunomedics, Inc.'s research and development focus. The report includes information on current ...

PropThink Biotech Stocks to Buy with Big Gains: Cubist, Immunomedics and More

Thu, 23 May 2013 12:32:48 GMT

PropThink Biotech Stocks to Buy with Big Gains: Cubist, Immunomedics and More
24/7 Wall St. - May 23, 2013

Immunomedics Inc. (NASDAQ: IMMU) is on the radar screen as a possible option trade candidate. Immunomedics is a biopharmaceutical company engaged in the research, development, manufacture and marketing of monoclonal, antibody-based products ...

Biotech Most Volatile Stock, Celsion Corporation, Affymax, VIVUS, Sarepta ...

Fri, 31 May 2013 16:21:51 GMT

Biotech Most Volatile Stock, Celsion Corporation, Affymax, VIVUS, Sarepta ...
PR Carbon (press release) - May 31, 2013

It's been reported Celsion Corporation (NASDAQ:CLSN) announced that it has received commitments from institutional investors to buy an aggregate of $9.83 million of the Company's common stock, in an at-the-market registered direct offering, which was ...